10-Q: Ernexa Therapeutics Faces Going Concern Amid Q3 Loss, Capital Raise

Ernexa Therapeutics Inc. reported a reduced net loss for Q3 2025, driven by cost efficiencies and a recent $7.2 million capital raise, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Ernexa Therapeutics Inc. reported a net loss of $1.2 million for the three months ended September 30, 2025, a significant reduction from $26.6 million for the same period in 2024.
• For the nine months ended September 30, 2025, the net loss was $12.6 million, down from $38.8 million in the prior year period.
• The company had no revenue for the three and nine months ended September 30, 2025, compared to $487k and $581k, respectively, in 2024, following the assignment of its customer contract to Factor Bioscience in September 2024.
• Cash and cash equivalents increased to $3.047 million as of September 30, 2025, from $1.729 million at December 31, 2024.
• The company raised $7.2 million in gross proceeds from a private placement of common stock and prefunded warrants during the nine months ended September 30, 2025.
• Operating expenses decreased significantly, with general and administrative expenses falling by $7.8 million for the nine months ended September 30, 2025, primarily due to a sublease termination and reduced professional fees.
• Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the next 12 months due to insufficient capital.
• A 1-for-15 reverse stock split was effected on June 12, 2025, and authorized shares were increased from 100 million to 150 million.
• The company recognized a $5.8 million non-cash forward sales contract expense for the nine months ended September 30, 2025, related to the private placement.
• Preclinical development of ERNA-101 for ovarian cancer is progressing, with IND enabling studies and IND submission expected by 2026, followed by a Phase I clinical trial in the same year.

Sentiment

Score: 3

Explanation: While the company reduced its net loss and operating cash burn, and successfully raised capital, the explicit 'substantial doubt about going concern' and lack of revenue are significant negative indicators. The capital raise was essential but came with a large non-cash expense and dilution. Preclinical progress is positive but far from commercialization.

Positives

• Net loss significantly reduced to $1.2 million for Q3 2025 from $26.6 million in Q3 2024, and to $12.6 million for the nine months ended September 30, 2025, from $38.8 million in the prior year period.
• Total operating expenses decreased by $6.237 million for the nine months ended September 30, 2025, primarily driven by a $7.847 million reduction in general and administrative expenses.
• Cash used in operating activities decreased by $6.422 million, from $12.291 million in the nine months ended September 30, 2024, to $5.869 million in the current period.
• Successfully raised $7.2 million in gross proceeds from a private placement of common stock and prefunded warrants during the nine months ended September 30, 2025, improving cash balance.
• Recognized a $0.7 million gain on extinguishment of debt from writing off time-barred accounts payable and accrued expenses.
• Preclinical studies for ERNA-101 in ovarian cancer showed reduction of tumor growth and a statistically significant survival advantage.
• Expected completion of IND enabling studies and IND submission for ERNA-101 by 2026, with a Phase I clinical trial anticipated in the same year.

Negatives

• No revenue was recognized for the three and nine months ended September 30, 2025, compared to $487k and $581k in the prior year periods, respectively.
• The company has an accumulated deficit of approximately $244.1 million as of September 30, 2025.
• Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for the twelve-month period subsequent to the issuance date of these financial statements.
• A non-cash charge of $5.8 million was recognized related to a forward sales contract for the nine months ended September 30, 2025.
• The company will need to raise additional capital and currently has no arrangements for such capital, with no assurances of obtaining it on acceptable terms or at all.
• Significant dilution occurred due to the issuance of common stock and prefunded warrants in the 2025 private placement and the 1-for-15 reverse stock split.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern for the next 12 months.
• The company will require substantial additional capital to fund operations and execute its business strategy, and there is no assurance it can raise adequate capital on a timely basis, on favorable terms, or at all.
• Inability to raise capital could lead to reduced expenses, bankruptcy, reorganization, merger, or cessation of operations, potentially resulting in stockholders losing all or part of their investment.
• Future equity or convertible debt financings may have a dilutive effect on existing stockholders.
• Debt financings may subject the company to restrictive covenants, operational restrictions, and security interests in its assets.
• Raising capital through collaborative arrangements may require relinquishing rights to technologies or granting sublicenses on unfavorable terms.
• Macroeconomic factors and financial market volatility may make equity or debt financings more difficult, costly, or dilutive.
• The company is involved in litigation, specifically Donoghue v. Cherington and Ernexa, alleging a Section 16(b) violation (short swing profits) by Charles Cherington.
• A three-year contingent consideration liability related to an April 2023 asset acquisition is tied to market cap milestones ($100 million and $200 million for at least ten consecutive trading days), expiring April 26, 2026.

Future Outlook

The company expects to complete Investigational New Drug (IND) enabling studies and submit an IND for its lead product candidate, ERNA-101, by 2026, with a Phase I clinical trial anticipated in the same year. It is also investigating ERNA-201 for inflammatory/auto-immune disorders. The company is actively seeking strategic partnerships to co-develop or out-license therapeutic assets and applying for research grants to expand developmental opportunities and raise non-dilutive capital. Management anticipates continued operating losses and explicitly states the need to raise additional capital to fund operations for the next 12 months, with no assurance of obtaining it on favorable terms.

Management Comments

• "We envision a future where cell therapies powered by synthetic iMSCs can offer new options for patients with limited treatment paths and our mission is to transform the treatment of cancer and autoimmune disease by developing scalable, affordable, off-the-shelf cell therapies that restore hope."
• "We expect to complete the Investigational New Drug (IND) enabling studies and IND submission by 2026 and to subsequently enter a Phase I investigator sponsored clinical trial in the same year."
• "We are also investigating anti-inflammatory cytokine (e.g. IL-10)-secreting iMSCs in inflammatory/auto-immune disorders like rheumatoid arthritis, which we refer to as ERNA-201."
• "Additionally, to expand our developmental opportunities and raise non-dilutive capital, we are actively seeking strategic partnerships to co-develop or out-license therapeutic assets and engage with potential collaborators, and we are currently applying for research grants, some of which will be used for research conducted at our Texas subsidiary, Ernexa TX2, Inc."
• "We will continue to focus on finding operational efficiencies that result in cost savings."
• "Based on our current financial condition and forecasts of available cash, we will not have sufficient capital to fund our operations for the 12 months following the issuance date of the accompanying condensed consolidated financial statements."
• "We can provide no assurance that we will be able to obtain additional capital when needed, on acceptable terms, or at all."

Industry Context

Ernexa Therapeutics operates as a preclinical-stage biotech company specializing in iMSC cell therapy for cancer and autoimmune diseases. This stage of development is characterized by high research and development expenses, significant operating losses, and a complete reliance on external financing, which is consistent with Ernexa's current financial profile. The explicit 'going concern' warning is a common disclosure for early-stage biotech firms that have not yet commercialized products and require substantial capital for lengthy and expensive drug development. The company's strategy of seeking strategic partnerships and research grants aligns with industry trends for securing non-dilutive funding and leveraging external resources to advance its pipeline.

Comparison to Industry Standards

• Ernexa's preclinical stage, significant R&D expenses, and lack of revenue are typical for biotech companies at this phase, which are focused on developing product candidates rather than generating sales.
• The 'going concern' warning is a standard disclosure for early-stage biotech firms that have not achieved profitability and depend on continuous external funding to support their operations and clinical development programs.
• The need for substantial additional capital to fund IND-enabling studies, IND submissions, and Phase I clinical trials for candidates like ERNA-101 is consistent with the high capital requirements of drug development in the biotech industry.
• The pursuit of strategic partnerships and research grants for non-dilutive capital and expanded developmental opportunities is a common and necessary strategy for preclinical biotech companies to manage funding needs and mitigate dilution.
• The 1-for-15 reverse stock split and subsequent capital raises, while dilutive, are frequently employed by smaller biotech companies to maintain stock exchange listing requirements and attract institutional investment, which is a common challenge in the sector.

Corporate Governance

Legal Proceedings

• Dennis J. Donoghue, a security owner, initiated a lawsuit against the Company (as a nominal defendant) and Charles Cherington (as defendant) on October 20, 2025, in the Southern District of New York (Case No. 25-cv-8653).
• The lawsuit alleges a violation of Section 16(b) of the Securities Exchange Act of 1934, 15 U.S.C. Section 78p(b), and seeks recovery of alleged short swing profits by Cherington.

Related Party Transactions

• Charles Cherington, who served on the company's board of directors from March 2021 to July 6, 2023, and currently owns approximately 37% of the company's outstanding common stock, participated in the September 2024 financing transactions and the March 2025 private placement (2025 SPA) under the same terms and conditions as all other investors.
• On March 11, 2025, and March 21, 2025, the company received $1.5 million and $0.8 million, respectively, from Charles Cherington for the issuance of two promissory notes. These notes, totaling $2.3 million including accrued interest, were repaid in full by offsetting with a receivable due to the company from Mr. Cherington for his purchase of shares in the 2025 private placement.

Stakeholder Impact

• **Shareholders**: Face significant dilution from recent capital raises and the 1-for-15 reverse stock split. There is a substantial risk of losing all or part of their investment if the company cannot resolve its going concern issues and secure additional funding. Potential for further dilution from future capital raises remains high.
• **Employees**: The company's ability to continue operations and fund its R&D pipeline directly impacts job security and the value of any stock-based compensation. Uncertainty regarding future capital raises could affect employee morale and retention.
• **Creditors**: The 'going concern' warning indicates increased risk for creditors, as the company's ability to satisfy liabilities in the normal course of business is in doubt without additional capital.
• **Customers/Partners**: The assignment of the previous customer contract means direct revenue from that source is no longer available. Future partnerships are crucial for non-dilutive capital and development, impacting potential collaborators' risk assessment.
• **Regulatory Authorities**: The company's financial condition and disclosures, particularly the going concern warning, will be under scrutiny by regulatory bodies like the SEC.

Next Steps

• Complete Investigational New Drug (IND) enabling studies for ERNA-101 by 2026.
• Submit IND for ERNA-101 by 2026.
• Enter a Phase I investigator sponsored clinical trial for ERNA-101 in 2026.
• Continue investigating ERNA-201 for inflammatory/auto-immune disorders like rheumatoid arthritis.
• Actively seek strategic partnerships to co-develop or out-license therapeutic assets.
• Engage with potential collaborators.
• Apply for research grants, some of which will be used for research conducted at Ernexa TX2, Inc.
• Raise additional capital to fund operations.
• Focus on finding operational efficiencies that result in cost savings.

Key Dates

Recommendation

The company explicitly states 'substantial doubt regarding its ability to continue as a going concern' for the next 12 months, indicating severe financial distress. While a recent capital raise provided some cash, it came with significant dilution and a large non-cash expense. The company has no revenue, a substantial accumulated deficit, and relies entirely on external financing for its preclinical R&D. The ongoing litigation against a major shareholder adds further uncertainty. Given the high risk of failure, the lack of a clear path to profitability, and the explicit going concern warning, a seasoned investor would likely recommend selling to avoid potential further losses.

Keywords

Ernexa Therapeutics, ERNA, 10-Q, Q3 2025, financial results, preclinical, iMSC therapy, cell therapy, cancer treatment, autoimmune disease, ERNA-101, ovarian cancer, ERNA-201, rheumatoid arthritis, capital raise, going concern, biotech, pharmaceutical, stem cell, reverse stock split